MY197202A - A liquid formulation of anti-tnf alpha antibody - Google Patents

A liquid formulation of anti-tnf alpha antibody

Info

Publication number
MY197202A
MY197202A MYPI2019005331A MYPI2019005331A MY197202A MY 197202 A MY197202 A MY 197202A MY PI2019005331 A MYPI2019005331 A MY PI2019005331A MY PI2019005331 A MYPI2019005331 A MY PI2019005331A MY 197202 A MY197202 A MY 197202A
Authority
MY
Malaysia
Prior art keywords
liquid formulation
tnf alpha
alpha antibody
antibody
tnf
Prior art date
Application number
MYPI2019005331A
Inventor
So Ra Yun
Youn Kyung Ko
Jineon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY197202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MY197202A publication Critical patent/MY197202A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a liquid formulation of an anti-TNF-? antibody, specifically to a liquid formulation of adalimumab. The most illustrative drawing: FIGURE 2
MYPI2019005331A 2017-03-16 2018-03-16 A liquid formulation of anti-tnf alpha antibody MY197202A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (en) 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibody

Publications (1)

Publication Number Publication Date
MY197202A true MY197202A (en) 2023-05-31

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019005331A MY197202A (en) 2017-03-16 2018-03-16 A liquid formulation of anti-tnf alpha antibody

Country Status (14)

Country Link
JP (2) JP7109849B2 (en)
KR (2) KR20180106974A (en)
CN (1) CN110621303A (en)
AU (1) AU2018236651B2 (en)
CO (1) CO2019010860A2 (en)
MA (1) MA46988A1 (en)
MX (1) MX2019010895A (en)
MY (1) MY197202A (en)
NZ (1) NZ757965A (en)
PH (1) PH12019502075A1 (en)
RU (1) RU2756619C2 (en)
UA (1) UA123847C2 (en)
WO (1) WO2018169348A1 (en)
ZA (1) ZA201906696B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120241997A (en) * 2019-02-18 2025-07-04 伊莱利利公司 Therapeutic antibody preparations
CN113727730A (en) * 2019-03-18 2021-11-30 阿尔沃科技Hf公司 Aqueous formulations of high concentration TNF alpha antibodies
TW202519263A (en) * 2019-03-21 2025-05-16 美商再生元醫藥公司 Stabilized formulations containing anti-il-33 antibodies
EP4108258A4 (en) * 2020-02-20 2024-03-06 Bio-Thera Solutions, Ltd. Anti-tnf-alpha antibody preparation, preparation method therefor and use thereof
JP2023533704A (en) * 2020-07-13 2023-08-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Viscosity-reducing excipients and combinations thereof for high-concentration protein formulations
WO2022178114A1 (en) * 2021-02-17 2022-08-25 Aptevo Research And Development Llc Compositions comprising 4-1bb and ox40 binding proteins and methods of use
JPWO2025013783A1 (en) 2023-07-07 2025-01-16

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821865B2 (en) * 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
JP2015509526A (en) * 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド Pharmaceutical formulation
PE20150964A1 (en) 2012-09-07 2015-07-25 Coherus Biosciences Inc STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB
BR112015017619A2 (en) * 2013-01-24 2017-11-21 Glaxosmithkline Ip Dev Ltd liquid formulation, use of a formulation, and kit
TW201513882A (en) 2013-03-15 2015-04-16 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2015134406A1 (en) 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
PT2946765T (en) * 2014-05-23 2016-11-10 Ares Trading Sa Liquid pharmaceutical composition
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (en) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Pharmaceutical anti-tnfalpha antibody formulation
US20180016333A1 (en) * 2015-01-28 2018-01-18 Mabxience, S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
JP7109849B2 (en) 2022-08-01
RU2019130728A (en) 2021-04-16
CN110621303A (en) 2019-12-27
KR102342292B1 (en) 2021-12-24
MA46988A1 (en) 2020-06-30
AU2018236651B2 (en) 2020-12-10
RU2756619C2 (en) 2021-10-04
WO2018169348A1 (en) 2018-09-20
AU2018236651A1 (en) 2019-10-31
KR20180106974A (en) 2018-10-01
BR112019019162A2 (en) 2020-04-14
PH12019502075A1 (en) 2020-09-14
CO2019010860A2 (en) 2020-01-17
UA123847C2 (en) 2021-06-09
MX2019010895A (en) 2019-11-05
JP2020510079A (en) 2020-04-02
RU2019130728A3 (en) 2021-04-16
JP2022097600A (en) 2022-06-30
KR20200096472A (en) 2020-08-12
ZA201906696B (en) 2020-08-26
NZ757965A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
CL2022000448A1 (en) Autoinjector (divisional application no. 201903061)
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MY197202A (en) A liquid formulation of anti-tnf alpha antibody
MX2020009649A (en) Monoclonal antibodies against bcma.
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
WO2017218707A3 (en) Bispecific checkpoint inhibitor antibodies
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2017003478A (en) Anti-fgfr2/3 antibodies and methods using same.
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
MY191581A (en) Anti-pd-1 antibodies
EA201791029A1 (en) ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
SG10201803042PA (en) Anti-tim-3 antibodies
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MY200328A (en) Kinase inhibitors and uses thereof
ZA201703510B (en) Antibodies, uses & methods
PH12018550160B1 (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
SG11201811429XA (en) Flow reactor
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
PH12019502694A1 (en) Anti-trkb antibodies
MX2019010367A (en) Aqueous anti-pd-l1 antibody formulation.
MY207387A (en) Methods for the production of methacrylates